Orion Oyj Management

Management Kriterienprüfungen 2/4

Orion Oyj's CEO ist Liisa Hurme , ernannt in Jan 2019, hat eine Amtszeit von 5.42 Jahren. Die jährliche Gesamtvergütung beträgt €819.50K , bestehend aus 81.6% Gehalt und 18.4% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.029% der Aktien des Unternehmens, im Wert von €1.59M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 1.6 Jahre bzw. 4.1 Jahre.

Wichtige Informationen

Liisa Hurme

Geschäftsführender

€819.5k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	81.6%
Amtszeit als Geschäftsführer	5.4yrs
Eigentum des Geschäftsführers	0.03%
Durchschnittliche Amtszeit des Managements	1.6yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	4.1yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Liisa Hurme im Vergleich zu den Einnahmen von Orion Oyj verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	€217m
Dec 31 2023	€820k	€668k	€217m
Sep 30 2023	n/a	n/a	€173m
Jun 30 2023	n/a	n/a	€306m
Mar 31 2023	n/a	n/a	€336m
Dec 31 2022	€106k	€106k	€350m

Vergütung im Vergleich zum Markt: LiisaDie Gesamtvergütung ($USD879.95K) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt UK ($USD3.34M).

Entschädigung vs. Einkommen: LiisaDie Bezüge der Mitarbeiter sind um mehr als 20 % gestiegen, während die Unternehmensgewinne im vergangenen Jahr um mehr als 20 % gesunken sind.

Geschäftsführer

Liisa Hurme (57 yo)

5.4yrs

Amtszeit

€819,500

Vergütung

Dr. Liisa Hurme, PhD (Biochemistry), has been President , Chief Executive Officer and Chairman of Managemenbt board at Orion Oyj since Novemnber 01, 2022. Dr. Hurme served as Senior Vice President, Global...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Liisa Hurme	President	5.4yrs	€819.50k	0.029% € 1.6m
Rene Lindell	Chief Financial Officer & Member of Group Executive Management Board	less than a year	keine Daten	keine Daten
Olli Huotari	Senior VP of Corporate Functions	21.7yrs	keine Daten	0.060% € 3.3m
Satu Ahomäki	Senior VP of Generics and Consumer Health Business Division & Member of the Exe. Mgmt. Board	16.4yrs	keine Daten	0.035% € 2.0m
Outi Vaarala	Sr. VP of Innovative Medicines	4yrs	keine Daten	0.010% € 568.8k
Juhani Kankaanpaa	Senior VP of Global Operations & Member of Executive Management Board	1.6yrs	keine Daten	0.0036% € 198.5k
Niclas Lindstedt	Senior VP of Animal Health Business Division & Member of the Exe. Mgmt. Board	1.4yrs	keine Daten	0.0045% € 249.6k
Hao Pan	Senior VP of the Branded Products Business Division & Member of the Exe. Mgmt. Board	1.4yrs	keine Daten	0.0094% € 519.9k
Julia Macharey	Senior Vice President of People & Culture and Member of Management Board	less than a year	keine Daten	keine Daten
Tuukka Hirvonen	Investor Relations & Financial Communications Officer	no data	keine Daten	keine Daten
Terhi Ormio	Vice President of Communications	15.2yrs	keine Daten	keine Daten
Virve Laitinen	Sr. VP of Corporate Strategy and Program Mgmt. Grp. Level Function & Head of CSPMO	less than a year	keine Daten	0.023% € 1.3m

1.6yrs

Durchschnittliche Betriebszugehörigkeit

55yo

Durchschnittliches Alter

Erfahrenes Management: 0M2ODas Führungsteam des Unternehmens gilt nicht als erfahren ( 1.6 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Mikael Silvennoinen	Independent Director	10.3yrs	€123.40k	0.0069% € 385.3k
Veli-Matti Mattila	Independent Chairman	3.3yrs	€61.40k	0.0066% € 367.0k
Henrik Stenqvist	Director	less than a year	keine Daten	keine Daten
Kari Aho	Independent Director	4.1yrs	€61.40k	0.062% € 3.5m
Ari Lehtoranta	Independent Director	7.3yrs	€72.40k	0.0036% € 201.8k
Maziar Doustdar	Independent Director	2.3yrs	€60.80k	0.0011% € 60.0k
Eija Ronkainen	Independent Director	8.3yrs	€61.40k	0.41% € 22.8m
Hilpi Rautelin	Independent Vice Chairman of the Board	7.3yrs	€81.10k	0.0073% € 404.2k
Karen Soerensen	Independent Director	2.3yrs	€66.80k	0.0011% € 60.0k

4.1yrs

Durchschnittliche Betriebszugehörigkeit

62yo

Durchschnittliches Alter

Erfahrener Vorstand: 0M2ODie Vorstandsmitglieder gelten als erfahren (4.1 Jahre durchschnittliche Amtszeit).

Orion Oyj Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Orion Corporation Announces Change in Orion Group Executive Management Board as of 31 May 2025

Orion Corporation Announces Appointments to Nomination Committee

Orion Corporation Announces Change in Executive Management Board, Effect as of 1 April 2024

Orion Corporation Announces Board and Committee Appointment

Orion Oyj Announces Retirement of Mikael Silvennoinen as Board Member

Orion Oyj Announces CFO Changes

Recent updates

Orion Corporation Announces Change in Orion Group Executive Management Board as of 31 May 2025

Orion Corporation Announces Appointments to Nomination Committee

First quarter 2024 earnings released

Orion Corporation Announces Change in Executive Management Board, Effect as of 1 April 2024

Orion Corporation Announces Board and Committee Appointment

Upcoming dividend of €0.81 per share

Full year 2023 earnings released: EPS: €1.55 (vs €2.49 in FY 2022)

Now 23% undervalued

Orion Oyj Announces Retirement of Mikael Silvennoinen as Board Member

Orion Oyj Announces CFO Changes

Orion Corporation Announces Phase 3 Clinical Trials with ODM-208 (MK-5684) posted to ClinicalTrials.gov Database

Orion Corporation Receives Fda Approval for Bonqat (Pregabalin Oral Solution)

New major risk - Earnings quality

Third quarter 2023 earnings released

Orion Group Appoints Julia Macharey as Senior Vice President, People & Cultur

Now 20% undervalued after recent price drop

Orion Oyj to Report First Half, 2024 Results on Jul 18, 2024

Second quarter 2023 earnings released

Now 26% undervalued after recent price drop

Orion Oyj Announces Resignation of Jari Karlson as Chief Financial Officer

Independent Chairman recently sold €76k worth of stock

First quarter 2023 earnings released

Upcoming dividend of €1.60 per share at 3.7% yield

Insider recently sold €233k worth of stock

Full year 2022 earnings released: EPS: €2.49 (vs €1.38 in FY 2021)

Orion Oyj Provides Earnings Guidance for the Year 2023

Orion Oyj Announces Positive CHMP Opinion for Darolutamide in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer

Orion Group Provides Earnings Guidance for the Full Year 2022

Orion Group Appoints Liisa Hurme as CEO, Effective 1 January 2023

Orion Oyj Announces Executive Changes

Orion Announces Approval of Additional Indication of Darolutamide in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (Mhspc) from U.S. FDA

Second quarter 2022 earnings released

Orion Oyj to Report Nine Months, 2023 Results on Oct 26, 2023

Orion Oyj to Report Q1, 2023 Results on Apr 27, 2023

Orion Oyj Revises Earnings Guidance for the Full Year 2022

Orion Oyj to Report Q2, 2022 Results on Jul 15, 2022

Orion Oyj (HLSE : ORNBV) acquired V.M.D. n.v./s.a. from Inovet Bv for €130 million.

Orion Oyj (HLSE : ORNBV) acquired V.M.D. n.v./s.a.from Inovet Bv for €130 million.

Orion Oyj Announces Executive Changes

First quarter 2022 earnings released

Orion Oyj Appoints Liisa Hurme as President and the Chair of the Executive Management Board, as of 1 November 2022

Upcoming dividend of €1.50 per share

Orion’S Collaboration Partner Bayer Submits Applications in the U.S. and Eu for Additional Indication of Darolutamide

Orion Corporation Announces Results from an Ongoing Phase I/II CYPIDES Trial of ODM-208 Present at ASCO-GU

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Orion Oyj Provides Earnings Outlook for the Year 2022

Orion Announces Arasens Trial with Darolutamide in Combination with Docetaxel and Androgen Deprivation Therapy Meets Primary Endpoint of Significantly Increasing Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Third quarter 2021 earnings released

Second quarter 2021 earnings released: EPS €0.40 (vs €0.54 in 2Q 2020)

Orion Oyj Provides Earnings Guidance for the Year 2021

Orion Oyj Recalls Multivita Forte Dietary Supplement from Consumers

Orion Animal Health’s Tessie® (tasipimidine) Receives Positive CVMP Opinion

Orion Corporation’s Clinical Trial Shows Significant Improvement for Chronic Pain Patients Using Virtual Reality Therapy

Orion Animal Health’s Bonqat® (Pregabalin) Receives Positive CVMP Opinion

First quarter 2021 earnings released: EPS €0.42 (vs €0.48 in 1Q 2020)

Orion Oyj Provides Earnings Guidance for the Year 2021

Upcoming Dividend of €1.50 Per Share

Full year 2020 earnings released: EPS €1.57 (vs €1.43 in FY 2019)

Revenue misses expectations

New 90-day low: €34.16

Full year 2020 earnings released: EPS €1.57 (vs €1.43 in FY 2019)

Revenue misses expectations

New 90-day low: €35.85

New 90-day low: €37.02

Tenax Therapeutics, Inc. Enters into Amendment to License Agreement with Orion Corporation

Orion Is Planning to Renew Its R&D Strategy and Organisation

New 90-day low - €38.01

Orion Oyj to Report First Half, 2021 Results on Jul 19, 2021